Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2018 Earnings Results

Catalyst Pharmaceuticals Misses on EPS, Stock Up 3.36%

Catalyst Pharmaceuticals reported a loss per share of $0.14, but the stock rose by 3.36% following the earnings announcement. The increase in stock price may reflect investor optimism despite the loss, as there were no revenue figures provided. The lack of guidance and management commentary leaves some uncertainty about future performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.14	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Unknown

No transcript is on record, and the analysis is based solely on numerical results.

Catalyst Pharmaceuticals Misses on EPS, Stock Up 3.36%

Key numbers

Management commentary

Catalyst Pharmaceuticals, Inc.

More earnings this week

Catalyst Pharmaceuticals Misses on EPS, Stock Up 3.36%

Key numbers

Management commentary